iShares Biotechnology ETF
IBB · IShares
$199.54
-$4.18 (-2.05%) today
20 Nov 2026 close · USD · AED 732.81
Returns
Up to a year
| Period | IBB | S&P 500 (SPY) |
|---|---|---|
| 1 month | -5.21% | -10.30% |
| 3 months | -5.35% | -9.32% |
| 6 months | +18.86% | -6.47% |
| This year | +18.34% | +1.95% |
| 1 year | +21.74% | +6.86% |
Longer term
| IBB | S&P 500 (SPY) | S&P 500 (SPY) | |||
|---|---|---|---|---|---|
| Total | A year | Total | A year | ||
| 2 years | +48.58% | +21.9% | +9.3% | ||
| 3 years | +69.02% | +19.1% | +16.3% | ||
| 5 years | +30.73% | +5.5% | +9.5% | ||
| 7 years | +78.22% | +8.6% | +13.6% | ||
| 10 years | +115.7% | +8.0% | +13.9% | ||
| Since inception | +760.1% | +11.1% | +10.6% | ||
$10,000 invested 10 years ago is $21,567 today.
Dividends reinvested, to 20 Nov 2026. Past returns are no guide to the future.
RiskWorst fall -39.8% (Aug 2021 to Jun 2022) · ups and downs 21.6% a year
Volatility, 3 years
21.6%
SPY 15.7%
Worst fall
-39.8%
Jun 2022
Worst calendar year
-21.4%
2016
Up months
61%
last 3 years
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
0.68
Return above US Treasury bills per unit of volatility
Beta vs S&P 500
0.65
Moves about 0.65% when SPY moves 1%
Correlation with S&P 500
0.45
1 means they move together; 0 means unrelated
Share of the benchmark's rises
99%
In months the benchmark rose
Share of the benchmark's falls
70%
In months the benchmark fell; lower is better
Over the last 36 months, from monthly total returns against S&P 500 (SPY).
What stands outAgainst 4 healthcare ETFs
What it holds
243 holdings · as of 18 Nov 2026
- 1GILEAD SCIENCES9.38%
- 2AMGEN INC8.58%
- 3VERTEX PHARMACEUTICALS7.91%
- 4REGENERON PHARMACEUTICALS6.77%
- 5MODERNA5.39%
- 6ARGENX SE ADR3.75%
- 7NATERA2.76%
- 8BIOGEN2.62%
- 9BEONE MEDICINES AG2.48%
- 10REVOLUTION MEDICINES2.24%
Download daily prices (CSV) · Compare with other ETFs · Today's ETF movers · My list
IBB, iShares Biotechnology ETF: summary
iShares Biotechnology ETF (IBB) is an equity ETF from IShares, launched on 5 Feb 2001. It is domiciled in the United States. The expense ratio is 0.44% a year. It manages $10.5 billion. It holds 243 securities. The price was $199.54 on 20 Nov 2026.
Compare with similar ETFs: Healthcare and biotech ETFs
Questions about IBB
What is the expense ratio of IBB?
0.44% a year. It comes out of the fund's assets, so the price and the returns shown are already after this cost.
What has IBB returned?
iShares Biotechnology ETF returned 21.7% over 1 year, 19.1% a year over 3 years, 5.5% a year over 5 years and 8.0% a year over 10 years, with dividends reinvested.
What should UAE residents know before holding IBB?
IBB is domiciled in the United States, so its shares count as US assets. If a person who is not a US citizen or resident dies holding more than US$60,000 of US assets, US estate tax can apply, at rates up to 40%. The UAE has no income tax treaty with the United States, so dividends usually have 30% withheld. Ireland-domiciled UCITS ETFs are generally not treated as US assets for estate tax, and pay 15% on US dividends under the US and Ireland treaty. Confirm your own position with a tax adviser.
For investors living in the UAE
This ETF is domiciled in the United States, so its shares count as US assets. If a person who is not a US citizen or resident dies holding more than US$60,000 of US assets, US estate tax can apply, at rates that rise to 40%.
The UAE has no income tax treaty with the United States, so US dividends paid to a UAE resident usually have 30% withheld. Ireland-domiciled UCITS ETFs that hold US shares are generally not treated as US assets for estate tax, and the fund pays 15% on its US dividends under the US and Ireland treaty.
UCITS alternatives to IBB in US dollars
The biggest Irish-domiciled funds of the same kind (Healthcare and biotech ETFs) that trade in US dollars.
- XDWH.LXtrackers MSCI World Health Care UCITS ETF 1C0.25% a year · $4.3 billion
- IUHC.LiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · $3.4 billion
- HEAL.LiShares Healthcare Innovation UCITS ETF0.40% a year · $1.5 billion
The outcome depends on your nationality, residence and facts, so confirm your own position with a tax adviser. Sources: IRS, estate tax for nonresidents and US income tax treaties, checked October 2026.
About this data
ETF data comes from RuDo Wealth market data, with returns as of 20 Nov 2026. We order ETFs by published measures such as returns, volatility, cost and size, and we do not label any ETF as the best. Method reviewed by Alok Kumar, Chief Executive Officer, RuDo Digital Wealth, October 2026.
RuDo Wealth is a fee-only cross-border advisory operating through two separate companies. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. The entity permitted to serve you depends on your country of residence.
This page is general information, not a recommendation to buy or sell this ETF. Tax on ETF gains, dividends and estates depends on where you live and where the ETF is domiciled, so confirm your own position with a tax adviser. Past performance does not indicate future returns.











